- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00357552
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Standard effective antiretroviral therapy for HIV infected individuals includes three-drug combinations of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a PI or an NNRTI. However, three-drug regimens may not be ideal in resource-limited settings, where viral load and resistance testing may not be readily available. The purpose of this study is to evaluate the safety and efficacy of the PI LPV/r alone in treatment-experienced, PI-naive HIV infected individuals who are experiencing virologic failure on three-drug regimens.
This study will last 104 weeks. All participants will receive LPV/r twice daily for up to 104 weeks. Participants who experience virologic failure will receive emtricitabine/tenofovir disoproxil fumarate once daily in addition to LPV/r twice daily for the remainder of the study.
There will be 16 study visits for participants on LPV/r monotherapy and 12 study visits for participants who have intensified LPV/r with emtricitabine/tenofovir disoproxil fumarate. Blood collection and clinical assessment will occur at all visits; urine collection and resistance testing will occur at selected visits.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Lilongwe, Malauí
- University of North Carolina Lilongwe CRS (12001)
-
-
-
-
-
Chiang Mai, Tailândia, 50202
- Chiang Mai University ACTG CRS (11501)
-
-
-
-
-
Moshi, Tanzânia
- Kilimanjaro Christian Medical CRS
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, África do Sul
- Wits HIV CRS (11101)
-
-
-
-
-
Chennai, Índia
- Y.R.G Ctr, for AIDS Research and Education (11701)
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria for Step 1 Participants:
- HIV infected
- Continuous treatment with a three-drug, NNRTI-containing regimen for at least 6 months prior to study entry
- Viral load of 1,000 copies/ml or greater and less or equal to 200,000 copies/ml obtained within 30 days of study entry
- Negative pregnancy test within 48 hours of study entry
- Willing to use acceptable forms of contraception for the duration of the study
Laboratory values obtained within 30 days of study entry:
- Hemoglobin greater or equal to 8.0 g/dL
- Platelet count greater or equal to 50,000/mm3
- Estimated Creatinine Clearance greater or equal to 60 mL/min x ULN
- AST (SGOT), ALT (SGPT) and alkaline phosphatase < 3 x ULN
- Total bilirubin less or equal to 2.5 x ULN
- Ability and willingness of participant or legal guardian/representative to give informed consent
Inclusion Criteria for Step 2 Participants:
- Virologic failure on LPV/r monotherapy defined as viral load of 400 copies/ml or greater after 24 consecutive weeks on LPV/r monotherapy OR virologic failure after initial viral suppression on LPV/r monotherapy
- Estimated creatinine clearance of 60 ml/min or greater
- Negative pregnancy test within 48 hours of entry into Step 2
- Willing to use acceptable forms of contraception for the duration of the study
Exclusion Criteria for All Participants:
- Breastfeeding
- Known allergy or sensitivity to study drugs
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with study adherence to study requirements
- History of chronic hepatitis B infection
Exclusion Criteria for Step I Participants:
- Prior use of any protease inhibitor treatment
- Acute therapy for any serious medical condition within 14 days of study entry. For ongoing or chronic therapy, the participant must be on the treatment regimen for at least 14 days, and clinically stable prior to entry. If a potential participant has TB and has received treatment for more than 2 weeks, the TB treatment would have to be modified to include a rifabutin-containing regimen. TB compatible syndromes will also be carefully evaluated prior to entry.
Exclusion Criteria for Step 2 Participants:
- Active opportunistic infection, including tuberculosis (TB)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: LPV/r monotherapy
Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks.
Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
|
Once daily
Outros nomes:
Twice daily
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy
Prazo: From study entry to week 24
|
Virologic success at week 24 on LPV/r monotherapy was defined as remaining on LPV/r monotherapy at week 24 without prior virologic failure.
Virologic failure was met with either of these two conditions: (i) failure to suppress HIV-1 RNA to < 400 copies/mL by week 24 or (ii) confirmed HIV-1 RNA >= 400 copies/mL after confirmed HIV-1 RNA < 400 copies/mL.
|
From study entry to week 24
|
Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study.
Prazo: From study entry to week 24
|
Probability of Grade 3 or 4 sign or symptom, or laboratory toxicity over 24 weeks on study using Kaplan-Meier estimates of the cumulative probability of Grade 3 or 4 sign or symptom, or laboratory toxicity at week 24.
Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
|
From study entry to week 24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening.
Prazo: Screening
|
Number of screened subjects with at least one NNRTI, or NRTI-associated resistance mutation.
Resistance interpretations used the November 30, 2011 Stanford algorithm.
|
Screening
|
Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure.
Prazo: Study entry to Week 104
|
25th percentile in weeks from study entry to treatment failure, defined as the first occurrence of death, disease progression, or virologic failure.
Virologic failure was defined as HIV-1 >= 400 copies/mL after week 24 or 2 consecutive HIV-1 RNA >= 400 copies/mL after week 16 following suppression on LPV/r monotherapy.
|
Study entry to Week 104
|
Number of Participants With Study-targeted Diagnoses and Clinical Events
Prazo: Study entry to week 104
|
Cardiac disorders, Infections and infestations, Metabolism and nutrition disorders, Neoplasms benign, malignant and unspecified (including cysts and polyps), Pregnancy, puerperium and perinatal conditions, Vascular disorders, were specified a priori as study-targeted events by the study chair.
|
Study entry to week 104
|
Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure.
Prazo: At time of virologic failure
|
Number of subjects with at least one new PI-associated resistance mutation at time of virologic failure.
Resistance interpretations used the May 6, 2009 Stanford algorithm.
|
At time of virologic failure
|
Percentage of Subjects Reporting Not Skipping Medications in the Last Month.
Prazo: Study entry and weeks 2, 4, 8, 12, 16, 20, and 24
|
The percentage of subjects reporting never missing medications in the last month.
|
Study entry and weeks 2, 4, 8, 12, 16, 20, and 24
|
Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification
Prazo: From LPV/r intensification to week 104
|
25th percentile in weeks from study entry to first new grade 3 or 4 sign or symptom or laboratory toxicity following LPV/r intensification.
Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
|
From LPV/r intensification to week 104
|
Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma
Prazo: At study entry and weeks 24 and 48
|
Proportion of DBS samples with HIV-1 RNA level <= 400 copies/mL, proportion of plasma samples with HIV-1 RNA level <= 400 copies/mL and proportion of paired DBS and plasma samples that are concordant (both <= 400 copies/mL or both > 400 copies/mL).
Results are pooled over 4 different storage temperature conditions (-80C, -20C, 4C and room temperature).
|
At study entry and weeks 24 and 48
|
HIV-1 Viral Sequence as Ascertained From Paired DBS and Plasma
Prazo: At study entry and virologic failure
|
HIV-1 viral sequencing as ascertained from paired DBS and plasma
|
At study entry and virologic failure
|
Proportion of Participants With Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104
Prazo: At Weeks 0, 12, 16, 20, 24, 32, 40, 48, 56, 68, 80, 92, 104
|
At Weeks 0, 12, 16, 20, 24, 32, 40, 48, 56, 68, 80, 92, 104
|
|
Change in CD4+ Cell Counts From Study Entry to Week 104
Prazo: Study entry and week 104
|
Study entry and week 104
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Nagalingeswaran Kumarasamy, MBBS, PhD, Y. R. Gaitonde Centre for AIDS Research and Education
- Cadeira de estudo: John Bartlett, MD, Division of Infectious Diseases, Duke University Medical Center
Publicações e links úteis
Publicações Gerais
- Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, Gonzalez-Garcia JJ, Cepeda C, Hervas R, Pano JR, Gaya F, Carcas A, Montes ML, Costa JR, Pena JM. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4.
- Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005 Mar 4;19(4):447-9. doi: 10.1097/01.aids.0000161777.38438.ed. No abstract available.
- Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004.
- Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066.
- Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis. 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Doenças do sistema imunológico
- Infecções por HIV
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores da transcriptase reversa
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Inibidores de Protease
- Inibidores do citocromo P-450 CYP3A
- Inibidores da enzima citocromo P-450
- Inibidores da Protease do HIV
- Inibidores de Protease Viral
- Tenofovir
- Emtricitabina
- Ritonavir
- Lopinavir
- Emtricitabina, Fumarato de Tenofovir Disoproxil Combinação de Medicamentos
Outros números de identificação do estudo
- ACTG A5230
- 1U01AI068636 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Infecções por HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
CDC FoundationGilead SciencesDesconhecidoProfilaxia pré-exposição ao HIV | Quimioprofilaxia HIVEstados Unidos
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
-
National Taiwan UniversityRecrutamento
Ensaios clínicos em Emtricitabine/Tenofovir disoproxil fumarate
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkConcluídoInfecções por HIVÁfrica do Sul, Uganda, Zimbábue
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkConcluídoInfecções por HIVZimbábue, Uganda
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Concluído
-
Samjin Pharmaceutical Co., Ltd.Concluído
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecrutamentoInsuficiência Cardíaca DescompensadaEstados Unidos
-
University of WashingtonBill and Melinda Gates FoundationConcluídoInfecções por HIV | Infecções por HIV-1Quênia, Uganda
-
Samjin Pharmaceutical Co., Ltd.Concluído
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ConcluídoSaudávelEstados Unidos
-
Daewoong Pharmaceutical Co. LTD.C&R Research, Inc.ConcluídoHepatite B CrônicaRepublica da Coréia
-
Merck Sharp & Dohme LLCAtivo, não recrutandoProfilaxia | Vírus da Imunodeficiência Humana Tipo 1 | HIV-1Estados Unidos, África do Sul, Uganda